On March 29, 2025, Titan Pharmaceuticals agreed to issue 100,000 shares of Series B Convertible Preferred Stock to Blue Harbour Asset Management for $1,000,000, with a conversion rate of $3.00 per share, and appointed Gabriel Loh as an independent director on March 27, 2025.